M184V/I does not impact the efficacy of abacavir/lamivudine/dolutegravir use as switch therapy in virologically suppressed patients
In: Journal of Antimicrobial Chemotherapy, Jg. 75 (2020-02-17), S. 1290-1293
Online
unknown
Zugriff:
Background M184V/I NRTI resistance mutations can be selected by either lamivudine/emtricitabine or abacavir. There are controversies about the use of abacavir/lamivudine/dolutegravir combinations in HIV-1-infected treatment-experienced patients with a fully suppressed HIV viral load (VL) and harbouring M184V/I. Objectives We assessed the efficacy of abacavir/lamivudine/dolutegravir when used in HIV-infected pretreated patients with an undetectable VL who previously harboured M184V/I as a unique NRTI resistance mutation in a genotypic resistance test and had no resistance to integrase inhibitors. Patients and methods A total of 154 patients with a fully suppressed HIV-1 plasma VL ( Results During the 12 months of follow-up, three patients had a blip of VL (53, 62 and 106 copies/mL) at Month 3 followed by a subsequent VL Conclusions M184V/I as a unique NRTI resistance mutation, regardless of possible selection by regimens containing lamivudine/emtricitabine or abacavir, does not affect the virological response of well-controlled patients who switched to abacavir/lamivudine/dolutegravir for at least 12 months.
| Titel: |
M184V/I does not impact the efficacy of abacavir/lamivudine/dolutegravir use as switch therapy in virologically suppressed patients
|
|---|---|
| Autor/in / Beteiligte Person: | Marcelin, Anne-Geneviève ; Descamps, Diane ; Minh Patrick Lê ; Peytavin, Gilles ; Jary, Aude ; Charpentier, Charlotte ; Wirden, Marc ; Calvez, Vincent ; Institut Pierre Louis d'Epidémiologie et de Santé Publique (iPLESP) ; Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU) ; Service de virologie [CHU Pitié-Salpêtrière] ; CHU Pitié-Salpêtrière [AP-HP] ; Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU) ; Infection, Anti-microbiens, Modélisation, Evolution (IAME (UMR_S_1137 / U1137)) ; Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Paris (UP)-Université Sorbonne Paris Nord ; Service de Virologie [CHU Bichat] ; Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-AP-HP - Hôpital Bichat - Claude Bernard [Paris] ; Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP) ; Gestionnaire, Hal Sorbonne Université ; Service de Virologie [CHU Pitié-Salpêtrière] ; Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris Cité (UPCité)-Université Sorbonne Paris Nord |
| Link: | |
| Zeitschrift: | Journal of Antimicrobial Chemotherapy, Jg. 75 (2020-02-17), S. 1290-1293 |
| Veröffentlichung: | Oxford University Press (OUP), 2020 |
| Medientyp: | unknown |
| ISSN: | 1460-2091 (print) ; 0305-7453 (print) |
| DOI: | 10.1093/jac/dkaa019 |
| Schlagwort: |
|
| Sonstiges: |
|